Canopy Growth (NASDAQ:CGC) shares have attracted significant attention this week, following reports that President Donald Trump plans to reclassify cannabis as a “Schedule III” drug. Alongside this, the president is considering a Medicare pilot program allowing select seniors to access cannabis products at subsidized rates.

These developments have created optimism across the cannabis sector, with Canopy Growth stock jumping roughly 90% from its late November lows. Investors are now asking whether CGC shares still offer room for growth heading into 2026.

Why Canopy Growth Stock Is Gaining Momentum

Federal policy changes are expected to be transformative for cannabis companies like Canopy Growth (NASDAQ:CGC). Easing banking restrictions and reducing the tax burden could attract institutional investors, unlock revenue potential, and accelerate the path to profitability.

Beyond policy tailwinds, Canopy Growth has strengthened its market position through strategic acquisitions. Its recent purchase of MTL Cannabis for approximately $179 million is poised to expand CGC’s domestic market share while adding high-margin revenue streams. This move reinforces the company’s long-term growth prospects and positions it to benefit from a growing legal cannabis market.

Technical indicators also point to bullish momentum. Canopy Growth stock is trading well above its 50-day, 100-day, and 200-day moving averages, signaling that buyers remain firmly in control as 2026 approaches.

Strong Financial Position Supports Growth

Financially, Canopy Growth stock is increasingly attractive. In its latest reported quarter, the company narrowed its adjusted EBITDA loss to just $3 million, supported by strong demand in the Canadian adult-use market.

CGC also maintains nearly $300 million in liquidity, providing flexibility to pursue expansion initiatives without immediate financial pressure. This liquidity position is critical for executing acquisitions, investing in product innovation, and expanding operational capacity.

The company’s historical performance adds further confidence. Since 2015, Canopy Growth stock has averaged a 12% gain in January, suggesting that momentum often carries over into the new year. For investors seeking exposure to cannabis ahead of potential policy reform, this historical trend is noteworthy.

Wall Street Analysts Stay Bullish

Analyst sentiment for Canopy Growth stock remains supportive. While the consensus rating currently sits at “Hold,” the mean price target of $2.62 implies roughly 30% upside from current levels. Analysts are citing both policy catalysts and operational progress as reasons to maintain a positive outlook on CGC.

Canopy Growth’s strategic positioning and improving fundamentals provide additional rationale for investors to consider accumulating shares. The company is not only benefiting from favorable policy but also leveraging acquisitions and operational efficiencies to strengthen its competitive position.

Opportunities Beyond U.S. Federal Policy

The anticipated federal reclassification of cannabis as Schedule III could create ripple effects across the global cannabis industry. Easier access to banking, insurance, and capital markets may unlock previously inaccessible growth opportunities. Canopy Growth (NASDAQ:CGC), with its established brand and diversified product portfolio, is well-placed to capitalize on these trends.

Additionally, Canopy Growth’s focus on premium and medical cannabis products offers high-margin revenue potential. The company’s efforts to expand domestic market share, combined with potential policy shifts in the United States, may position it as one of the leaders in the next wave of cannabis commercialization.

Conclusion

Canopy Growth stock has demonstrated impressive resilience and upside potential in 2025, driven by federal policy optimism, strategic acquisitions, and strong financial fundamentals. Analysts see additional upside of 30% to 40% from current levels, making CGC an intriguing prospect for growth-focused investors in 2026.

With supportive technical trends, nearly $300 million in liquidity, and a history of strong January performance, Canopy Growth (NASDAQ:CGC) offers both momentum and strategic opportunity. Investors should monitor developments in U.S. cannabis legislation closely, as policy implementation could further accelerate gains for this leading cannabis stock.

Featured Image: Megapixl @ Chernetskaya

Disclaimer